Although most antibody responses are initiated in secondary lymphoid organs, long-lived IgGsecreting plasma cells are located predominantly in the BM (1) (2) (3) . The homing of IgG plasmablasts and plasma cells (hereafter referred to in combination as antibody-secreting cells [ASCs] ) to the BM occurs only gradually and to a low level in the primary response but is rapid in the secondary response (1, 4) . Studies with nonreplicating antigens showed that ASCs were abundant in blood at day 3 of the secondary response but were few in number by day 7 (5, 6) . Splenectomy at day 2 of the secondary response to sheep red blood cells (SRBCs) largely prevented ASCs from appearing in the BM, whereas splenectomy at day 4 had little impact on the number of BM ASCs (7) . IgG ASCs in blood affi nity mature in parallel with BM ASCs, supporting the view that blood ASCs are in transit to the BM (8) .
Homing of ASCs to the BM is in part dependent on the chemokine receptor CXCR4 (9) (10) (11) . The CXCR4 ligand, SDF-1 (CXCL12), is abundantly expressed in the BM and is also strongly expressed in the red-pulp (RP) of spleen and in the medullary cords in LNs (6, 12) . ASCs that lack CXCR4 fail to localize appropriately in the splenic RP and LN medullary cords and fail to accumulate to normal numbers in the BM (6, 9) . However, CXCR4-defi cient ASCs are found in elevated numbers in the blood, indicating that this receptor is not essential for the cells to egress from secondary lymphoid organs (6) .
Recent studies have identifi ed an important role for sphingosine-1-phosphate (S1P) receptors in lymphocyte egress from secondary lymphoid organs. Initial studies with the immunosuppressant compound, FTY720, showed that it inhibits lymphocyte egress from LNs and Peyer's patches (13) . The eff ects of FTY720 After induction in secondary lymphoid organs, a subset of antibody-secreting cells (ASCs) homes to the bone marrow (BM) and contributes to long-term antibody production. The factors determining secondary lymphoid organ residence versus BM tropism have been unclear. Here we demonstrate that in mice treated with FTY720 or that lack sphingosine-1-phosphate (S1P) receptor-1 (S1P 1 ) in B cells, IgG ASCs are induced and localize normally in secondary lymphoid organs but they are reduced in numbers in blood and BM. Many IgG ASCs home to BM on day 3 of the secondary response and day 3 splenic ASCs exhibit S1P responsiveness, whereas the cells remaining at day 5 are unable to respond. S1P 1 mRNA abundance is higher in ASCs isolated from blood compared to spleen, whereas CXCR4 expression is lower. Blood ASCs also express higher amounts of Kruppel-like factor (KLF)2, a regulator of S1P 1 gene expression. These fi ndings establish an essential role for S1P 1 in IgG plasma cell homing and they suggest that differential regulation of S1P 1 expression in differentiating plasma cells may determine whether they remain in secondary lymphoid organs or home to BM.
on egress from the spleen have been diffi cult to assess because cell entry and exit both occur via the blood. After injection, FTY720 is rapidly phosphorylated and FTY720-P is a ligand for S1P receptors 1, 3, 4, and 5 (14, 15) . SIP receptor 1 (S1P 1 ) is essential for blood vessel development, and mice lacking this receptor die at embryonic day 13.5-14.5 (16) . Studies in fetal liver chimeras or in tissue-specifi c knockout mice showed that T cells lacking S1P 1 are unable to exit the thymus, and S1P 1 -defi cient B and T cells are ineffi cient in exiting secondary lymphoid organs (17, 18) . S1P is abundant in circulation and low in secondary lymphoid organs, and lymphocytes are thought to egress in response to S1P (19) . FTY720 treatment was not found to aff ect the antibody response to lymphocytic choriomeningitis virus or vesicular stomatitis virus (20) , whereas in a recent study it reduced both the splenic and BM ASC response to 4-hydroxy-3-nitrophenyl-acetyl coupled to chicken γ-globulin (NP-CGG) in alum (21) . However, the infl uence of FTY720 or S1P 1 on ASC egress from lymphoid organs has not been directly assessed. Since ASCs downregulate expression of CXCR5 and CCR7 and migrate to splenic RP and LN medullary cords-egress sites from these organs-in a CXCR4-dependent manner, it has been unclear whether they will use the same egress mechanisms as naive lymphocytes.
Here we have examined the possibility that diff erential S1P 1 expression contributes to promoting release versus retention of ASCs in secondary lymphoid organs. We show that FTY720 treatment inhibits IgG ASC egress from spleen and LNs. Using a mixed chimera approach we provide evidence that S1P 1 is required in B lineage cells for IgG ASC egress from the spleen and accumulation in the BM. In the secondary response, day 3 but not day 5 splenic ASCs and day 3 blood ASCs demonstrate responsiveness to S1P, and blood ASCs express higher amounts of S1P 1 than splenic ASCs. Blood ASCs are also found to have reduced CXCR4 expression compared with splenic ASCs, and they express higher amounts of Kruppel-like factor (KLF)2, a regulator of S1P 1 transcription. These fi ndings suggest that diff erential S1P 1 expression is a control point for secondary lymphoid organ retention versus egress into circulation and subsequent BM homing of newly developing IgG ASCs.
RESULTS

FTY720 treatment inhibits IgG ASC entry into blood and homing to BM
To test the impact of FTY720 treatment on ASC homing during the primary response, mice were immunized with the T cell-dependent antigen, NP-CGG in the adjuvant alum, and then at day 4 and 7 with FTY720. The frequency of ASCs in spleen and BM was then determined at day 7 and 10 ( Fig. 1 A) . The FTY720 treatment was delayed until day 4 to limit eff ects on the initial recruitment of recirculating antigen-specifi c B and T cells. The IgG ASC frequency in the spleen was little aff ected by the FTY720 treatment (Fig.  1 A) . In contrast, there was a decrease in the number of IgG ASCs in the BM at day 7 and 10 ( Fig. 1 B) . Similarly, s.c. immunization led to appearance of IgG ASCs in the draining LNs, and FTY720 treatment did not greatly aff ect this response. However, FTY720 largely inhibited the appearance of IgG ASCs in the BM after s.c. immunization (Fig. 1,  A and B) .
Eff orts to determine whether there was an eff ect on ASC egress from lymphoid organs into the blood were hampered 
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by the low numbers of ASCs entering into the blood during the primary response. We therefore performed secondary immunizations, treating the mice with FTY720 at day 1.5 after secondary immunization since BM homing via the blood occurs by day 3 of the secondary response (7) . Again the treatment had little eff ect on the IgG ASC number in the spleen (Fig. 1 A) . A baseline of NP-specifi c IgG ASCs were detected in the BM because of the primary immunization, but the number was increased twofold by day 3 and four-to fi vefold by day 7 in the control group. FTY720 treatment inhibited the increase in BM ASC number (Fig. 1 B) . IgG ASCs were readily detectable in the blood of control mice at day 3 and were largely gone by day 7 (Fig. 1 C) . In contrast, few if any IgG ASCs appeared in the blood of FTY720-treated mice (Fig. 1 C) . We also asked whether FTY720 could aff ect BM homing after ASCs had entered the blood, by adoptively transferring spleen cells from mice at day 3 of the secondary response into unimmunized recipients that were either untreated or treated 1 d before with FTY720.
ELISPOT analysis 1 d after transfer revealed similar numbers of donor-derived NP-specifi c ASCs in the BM of control and FTY720-treated mice (Fig. 1 D) . Thus, FTY720 treatment inhibits the migration of IgG ASCs from spleen into blood but does not inhibit the homing of adoptively transferred IgG ASCs from blood to BM.
Intrinsic S1P 1 requirement for BM homing S1P 1 is abundant in naive lymphocytes and is required in these cells for egress from lymphoid organs (17, 18) . S1P 1 is also abundant in endothelial cells (22) . The ability of FTY720 to inhibit cell egress from lymphoid organs may be caused by agonistic eff ects on endothelial cells, down-modulation of receptors on immune cells, or disruption of S1P gradients (23) (24) (25) . To test whether there was an intrinsic requirement for S1P 1 in ASCs for egress we reconstituted lethally irradiated Igh b mice with S1P 1 −/− Igh a fetal liver cells and small numbers of Igh b WT BM cells as a source of WT T cells. After a 6-wk reconstitution, the mice were primed and then boosted with NP-CGG in alum. In mixed chimeric animals that mounted similar day 3 splenic IgG ASC responses ( Fig. 2 A) , very few S1P 1 −/− ASCs could be detected in the BM at day 3 or day 7 ( Fig. 2 B) . Consistent with S1P 1 being required for ASC egress from the spleen, very few IgG ASCs could be detected in the blood at day 3, whereas IgG ASCs could be detected in the blood of WT chimeras (Fig. 2 C) .
Immunohistochemical analysis revealed that the distribution of IgG ASCs in FTY720-treated mice at day 5 of the secondary response was similar to their distribution in salinetreated controls (Fig. 3 A) . Side-by-side comparison of the distribution of S1P 1 −/− IgG1 a and S1P 1 +/+ IgG1 b ASCs in the spleen of mixed chimeras further demonstrated that this pathway is not required for positioning of IgG ASCs in clusters within the RP (Fig. 3 B) .
S1P responsiveness
As a read-out of S1P 1 function we examined the ability of ASCs to migrate in response to S1P. We compared the response of IgG ASCs from spleen at day 3 versus day 5 of the secondary response because previous studies have established that the majority of ASCs egress at day 3 with few cells continuing to egress into blood at day 5 (1). Day 3 but not day 5 splenic IgG ASCs showed a small but signifi cant (P < 0.05) chemotactic response to S1P (Fig. 4 A) . ASCs at both time points demonstrated a similar responsiveness to SDF-1 (Fig.  4 A) . Consistent with previous demonstrations that high dose FTY720 treatment ablates S1P responsiveness in lymphocytes, cells from the treated mice had lost the ability to respond to S1P while continuing to respond to SDF-1 (Fig. 4 A) . We also tested the ability of IgG ASCs from the blood to chemotax to S1P. Two technical diffi culties with this experiment were the very small numbers of ASCs present in blood and the presence of large amounts of S1P in blood that down-regulate and desensitize S1P 1 (26) . In preliminary experiments, we found it diffi cult to wash the cells free of blood S1P. However, when the CD45.1 blood cells were mixed with a 10-fold excess of CD45.2 spleen cells at the time of isolation and washing and then the spleen cells depleted using antibodies to CD45.2, it was possible to reveal an S1P response in the blood cells, and this response exceeded that of spleen ASCs isolated in parallel and through the same steps (Fig. 4 B) .
An assessment of the migratory response to S1P was also performed using cells from immunized Blimp1 GFP reporter mice (27) . Blimp1 is up-regulated at an early step in ASC diff erentiation and is essential for plasma cell development and maintenance (28) . As previously observed, the ASCs induced in the spleen at day 3 of the secondary response were predominantly Syndecan1 + and GFP int (Fig. 5 A) , whereas there was an accumulation of Syndecan1 + GFP hi cells at later time points (27) . The ASCs in the blood at day 3 were consistently Syndecan1 + GFP int , and very few Syndecan1 + GFP hi cells were detected (reference 27 and unpublished data). In migration assays, the splenic GFP int cells showed a migratory response to S1P, whereas the GFP hi cells showed little response (Fig. 5, A and B) . The splenic GFP int cells also showed a robust response to SDF-1 (Fig. 5, A and B) . These fi ndings confi rm that the day 3 splenic ASC population contains S1P-responsive cells.
Analysis of ASCs that accumulate in E-and P-selectindefi cient mice showed that B220 int/lo cells were more chemokine responsive than B220 neg cells (29) . Our observations agree with these fi ndings because the migratory GFP int cells are B220 int/lo , whereas the poorly migratory GFP hi cells express little if any B220 (Fig. 5 A, bottom and reference 27 ). In addition, within the GFP int population, we saw a trend toward more S1P responsiveness in ASCs with higher amounts of B220 (Fig. 5 A, bottom) . However, B220 levels were not markedly diff erent between GFP int cells in spleen and blood (unpublished data). In the course of these experiments we observed that CXCR4 was expressed at intermediate levels on the surface of blood ASCs compared with splenic ASCs (Fig. 5 C) . Despite the lower CXCR4 expression, the magnitude of the blood and splenic ASC SDF-1 chemotactic responses appeared similar (Fig. 4 B) . A lack of direct correlation between ASC CXCR4 levels and SDF-1 chemotactic responses has been observed previously (29) (30) (31) . S1P 1 and KLF2 are more abundant in blood versus spleen ASCs To measure S1P 1 abundance in ASCs in blood versus spleen, Blimp1 GFP reporter mice were primed and boosted with NP-CGG and Syndecan1 + GFP int and GFP hi spleen cells or Syndecan1 + GFP + blood cells were purifi ed at day 3 of the response. The GFP int subset in the spleen was further divided into CXCR4 hi and CXCR4 int to explore the possibility that the CXCR4 int population contained cells that were the most Cells that migrated to the lower well of a transwell chamber in response to 0 or 100 nM S1P (left) or 0.3 μM SDF-1 (right) were analyzed by ELISPOT assay to detect IgG 1 -secreting cells. Bars represent means ± SD for six to eight samples from three experiments. A Student's t test was performed between the indicated groups. *, P < 0.05.
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closely related to the blood ASCs (Fig. 5 C) . Compared with naive B cells, GFP hi splenic ASCs had ‫-02ف‬fold reduced S1P 1 transcript levels (Fig. 6 A) . Splenic GFP int CXCR4 hi cells also showed a marked reduction in S1P 1 expression, whereas GFP int CXCR4 int cells showed a trend toward increased expression (Fig. 6 A) . GFP int ASCs sorted from the blood had amounts of S1P 1 that were within twofold of the levels detected in splenic B cells (Fig. 6 A) . Expression of S1P 2 , S1P 3 , S1P 4 , and S1P 5 in blood ASCs was low or undetectable (unpublished data). We also quantitated Blimp1 transcripts and found that they were undetectable in splenic and blood B cells and abundant in the ASCs as expected (unpublished data). Finally, we examined the abundance of KLF2 (also known as lung KLF), a transcription factor that can promote S1P 1 transcription (32, 33) , and found that levels were reduced in splenic GFP hi and GFP int CXCR4 hi ASCs (Fig. 6 B) . As for S1P 1 , KLF2 transcripts were more abundant in the splenic GFP int CXCR4 int subset than in GFP int CX-CR4 hi cells and levels in blood GFP int ASCs were similar to splenic B cells (Fig. 6 B) .
DISCUSSION
The above fi ndings demonstrate that egress of IgG ASCs from secondary lymphoid organs into blood and BM is sensitive to inhibition by FTY720 treatment and strongly dependent on intrinsic S1P 1 expression. S1P 1 abundance and S1P responsiveness is found to be low in most splenic ASCs but is detectable within a Blimp1 int CXCR4 int splenic ASC population and is most enriched in ASCs isolated from the blood. These fi ndings establish an important role for S1P 1 in IgG plasma cell homing and they suggest that diff erential regulation of S1P 1 expression in diff erentiating plasma cells may be a key factor determining whether they remain in secondary lymphoid organs or exit these organs to home to other sites, such as the BM. We also fi nd diff erential expression of KLF2 between splenic and blood ASCs, pointing to a possible role for this transcription factor in defi ning the gene expression program associated with the homing decision of diff erentiating plasma cells.
In a previous study, treatment with FTY720 from the day of primary immunization was found to reduce the magnitude of the IgG plasma cell and germinal center response (21) . This may have been a consequence of reduced recruitment of antigen-specifi c T cells from other sites caused by the generalized block in secondary lymphoid organ egress (34) . We delayed treatment of the mice for 4 d in the primary response or 1.5 d in the secondary response to provide an opportunity for recruitment of circulating antigen-specifi c B and T cells, and we found that the secondary lymphoid organ ASC responses were of similar magnitude in the treated and untreated groups, indicating that treatment did not severely aff ect the ability of the animals to mount an antibody response. In agreement with this conclusion, production of neutralizing antibodies after the fi rst 3 wk of lymphocytic choriomeningitis virus and vesicular stomatitis virus infection were unaff ected by low dose (0.3 mg/kg) FTY720 treatment (20) . The ability of S1P 1 -defi cient B cells to mount antibody responses also demonstrates that B cell expression of this receptor is not essential for B cell activation and diff erentiation. However, because of limitations in the mixed fetal liver/BM chimera approach, our experiments have not examined the effi ciency of each stage of the antibody and memory B cell response. Future experiments with mice carrying fl oxed alleles of S1P 1 (17) and B cell-selective Cre recombinase will be needed to more fully address the impact of ASCs and B cell S1P 1 defi ciency on maintenance of long-term antibody production and on B cell memory.
The mechanism by which FTY720 reduces lymphocyte egress from lymphoid organs is under active investigation (18, 35) , and it has been debated whether FTY720 impacts lymphocyte egress from the spleen (14) . Our fi ndings here provide evidence that egress of IgG ASCs from the spleen can be inhibited by FTY720 treatment. Although the pathway by which cells exit the spleen is not defi ned, it is likely that the cells need to reach RP sinusoids to return to circulation. Whether the ASCs that normally egress from the spleen correspond to cells that have fi rst traveled into the RP is not yet clear. However, like spleen and LN ASCs, blood ASCs are found to have down-modulated CXCR5 and CCR7 (and up-regulated CXCR4), making it likely that these cells migrate out of the white-pulp before exiting into circulation (6) . The lack of CXCR5 and CCR7 expression on these cells but the continued requirement for S1P 1 to permit effi cient egress indicates that the intrinsic function of S1P 1 cannot solely be to overcome the retention function of these chemokine receptors. However, it remains possible that CXCR4 normally participates in retaining cells in the spleen and LNs, and one function of S1P 1 may be to overcome CXCR4-mediated retention. In this regard it is notable that the Blimp1 GFP+ cells in the blood were CXCR4 int compared with the bulk of the Blimp1 GFP+ cells in the spleen. We propose that the reduced CXCR4 expression together with the increased S1P 1 expression in a subset of cells contributes to shifting the balance of signals in favor of S1P 1 and promoting egress. However, CXCR4 is only partially down-modulated, consistent with it also being required for lodgment of ASCs in the BM. Beyond this possible interplay, we anticipate that S1P 1 will be required during egress to overcome additional retention signals, provide directional information, and/or promote reverse transmigration across blood or lymphatic vessels. Although we have focused on the mobilization of IgG ASCs to the BM, we anticipate that similar requirements will exist for IgA ASC egress from mucosal lymphoid tissues before their homing to epithelial surfaces.
Our fi ndings suggest that defi nition of the mechanism by which a subset of diff erentiating ASC up-regulate S1P 1 may illuminate how ASCs choose between the secondary lymphoid organ versus BM (or mucosa) tropic plasma cell fate. This cell fate decision may also encompass becoming short versus long lived, though some studies have indicated that long-lived plasma cells (PCs) are present in secondary lymphoid organs and BM (36) and, reciprocally, some of the PC homing to BM may be short lived. Although our studies show that S1P 1 is necessary, our studies have not established Figure 6 . Quantitative PCR analysis of S1P 1 and KLF2 mRNA from B cells and plasma cells in spleen and blood. Spleen cells from Blimp-1 GFP/+ mice 3 d after immunization were sorted into B220 lo/− Syndecan + GFP hi , GFP int CXCR4 hi , and GFP int CXCR4 int ASC subsets and B220 + Syndecan − GFP − B cells. The CXCR4 int gate was assigned based on CXCR4 levels on blood GFP int cells stained in parallel (see Fig. 5 C for an example). Blood B220 lo/− Syndecan + GFP int cells were from 3-d-immunized mice. The amounts of S1P 1 (A) and KLF2 (B) mRNA were expressed as relative amount of the indicated mRNA normalized to HPRT. CXCR4 "total" indicates the cells were isolated without gating on CXCR4 levels. Filled circles indicate individual samples, and bars represent the average. The data are pooled from three to four independent experiments. A Student's t test was performed between the indicated groups. *, P < 0.05. that this receptor is suffi cient to determine whether an ASC undergoes egress or is retained, and additional diff erences between the cells may be important. The fi nding that KLF2, a transcription factor shown to directly induce S1P 1 expression in T cells (32, 33) , is increased in blood Blimp1 GFP+ cells is consistent with a role for this factor in promoting S1P 1 expression in ASCs. KLF2 regulates the expression of additional genes in T cells (32, 33) and it may regulate expression of further genes involved in the commitment of diff erentiating B cells to becoming BM tropic ASCs. Previous studies have suggested that BM tropic ASCs are induced predominantly from germinal center B cells or memory B cells (5, (37) (38) (39) . Indeed, the synchronized wave of ASCs traveling through the blood at day 3 of the secondary response most likely refl ects rapid diff erentiation of memory B cells into BM tropic ASCs. Although it is thought likely that these ASCs contribute to the pool of long-lived PCs, we have not established that this is the case for the cells tracked in the present study. Finally, although we were able to enrich based on intermediate CXCR4 and Blimp1 GFP expression for splenic ASCs with an egress-related phenotype, this cell population had lower amounts of S1P 1 and KLF2 than the cells isolated from blood, suggesting that we had only achieved partial enrichment. The future development of reagents that permit tracking of S1P 1 expression at the level of single B cells and ASCs should provide a method to isolate and further characterize the earliest cells that are taking on the BM tropic ASC fate.
MATERIALS AND METHODS
Mice and fetal liver chimeras. C57BL/6 (B6) and B6 CD45.1 mice were from the National Cancer Institute. Blimp1 GFP/+ mice were generated as described (27) . S1P 1 +/− mice (16) were crossed for at least fi ve generations to B6 or 129 mice, and then S1P 1 +/− mice were intercrossed. S1P 1 +/+ or S1P 1 −/− fetal liver cells were prepared at embryonic day 12.5 and genotyped by PCR (16) . Each preparation was mixed with B6 BM cells (1.5 × 10 5 and 3 × 10 6 cells, respectively) and transferred to reconstitute three lethally irradiated B6 CD45.1 mice (6). Mice were immunized 6 wk after reconstitution. For FTY720 treatment, B6 mice were injected i.p. with 3.0 mg/kg of FTY720 or with an equivalent volume of saline 4 and 7 d after primary and 1.5 d after secondary immunization. FTY720 was from a custom synthesis performed at SRI International. Animals were housed in a specifi c pathogen-free facility and all experiments were in accordance with protocols approved by the University of California San Francisco Institutional Animal Care and Use Committee.
Immunizations. B6 mice were immunized with 50 μg of alum-precipitated NP-CGG (Solid State Sciences) i.p. or s.c. in a volume of 200 μl. In some experiments, mice received a secondary immunization of the same type 3 wk later. Spleen, LNs, blood, and BM were harvested from mice at the indicated time points as described previously.
Flow cytometry and immunohistochemistry. Flow cytometric data were collected on a FACS LSRII (BD Biosciences) and analyzed using FlowJo software (Tree Star). Antibodies used were: biotin-conjugated anti-CXCR4 (2B11; BD Biosciences), PE-conjugated anti-Syndecan (281-2; BD Biosciences), APC-conjugated anti-B220 (RA3-6B2; BD Biosciences) and NP (40) , and APC-Cy7-conjugated anti-CD4 and CD8 (GK1.5, 53-6.7; BD Biosciences). Streptavidin-PE-Cy5.5 was from Caltag, and DAPI was used to exclude dead cells. Spleens of immunized B6 mice treated with or without FTY720 were frozen in Tissue-Tek OCT compound (Baxter Scientifi c). Cryostat sections (7 μm) were fi xed in acetone and stained as described previously (41) 
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A -TAMRA; and HPRT, S1P 1 , S1P 2 , S1P 3 , S1P 4 , and S1P 5 as reported (18) . KLF2 (and HPRT) was quantitated using SYBR Green (Bio-Rad Laboratories), and KLF2, forward,
T A T C T T G C C G T C C-T T T G C C A and reverse, T T A G G T C C T C A T C C G T G C C primers.
Chemotaxis assays. Cells were tested for transmigration across uncoated 5-μm transwell fi lters (Corning Costar Corp.) for 3 h to S1P (Sigma-Aldrich), SDF-1 (PeproTech), or medium in the bottom chamber and were enumerated by ELISPOT or, in the case of cells from Blimp1 GFP/+ mice, by fl ow cytometry (42) . To prepare blood cells for chemotaxis, 2 × 10 6 Ly5.1 Igh a RBC-lysed blood cells isolated by cardiac puncture were mixed with 10 8 Ly5.2 Igh b RBC-lysed spleen cells, incubated for 30 min at 37°C in DMEM 0.5% fatty acid-free BSA, washed twice, and then the Ly5.1 and Ly5.2 cells were separated using Ly5.2 and AutoMACS. Because of the low frequency of ASCs, the blood cells that migrated across 8 transwells and the spleen cells that migrated across 4 transwells in response to S1P were pooled and tested in the ELISPOT or FACS assays.
ELISPOT assays. Freshly isolated spleen, blood, BM, and LN cells were used in ELISPOT assays as described previously (6) . Plates were precoated with NP 25 
